Tenoxicam

證據等級: L5

預測適應症: 10 個

Tenoxicam: From NSAID Musculoskeletal Pain Management to Rheumatoid Arthritis

One-Sentence Summary

Tenoxicam is an oxicam-class NSAID with long-established use in osteoarthritis, ankylosing spondylitis, and inflammatory/postoperative pain. The TxGNN model ranks Rheumatoid Arthritis as its top predicted indication, but this is not a novel repurposing signal — it is corroborated by 1 clinical trial and 20 publications, including several decades-old RCTs that already demonstrate efficacy in RA specifically.

Quick Overview

Item	Content
Original Indication	Not documented in New Zealand market data (drug unmarketed); based on established oxicam/NSAID use, tenoxicam is indicated for osteoarthritis, ankylosing spondylitis, and other inflammatory/postoperative pain conditions
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.90%
Evidence Level	L2
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap). Based on known information, tenoxicam belongs to the oxicam class of NSAIDs (related to piroxicam), acting via inhibition of COX-1/COX-2 to reduce prostaglandin-mediated inflammation and pain. This anti-inflammatory mechanism is directly applicable to rheumatoid arthritis, an inflammatory joint disease.

Notably, the literature evidence for this prediction is not exploratory extrapolation — tenoxicam has been directly studied and compared against other NSAIDs (piroxicam, aceclofenac, naproxen) specifically in RA populations since the 1980s–1990s, with several completed RCTs. This means the TxGNN model's high score for RA largely reflects an already-established, well-documented use of the drug rather than a genuinely new therapeutic hypothesis. The value of this candidate lies less in novelty and more in confirming the model correctly recovers known pharmacology.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05508451	Phase NA	Completed	80	Compared tenoxicam, paracetamol, and tenoxicam-paracetamol combination for postoperative pain following double-jaw surgery. Not RA-specific; supports general analgesic/anti-inflammatory profile only (relevance grade B).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8894360	1996	RCT	Clinical Rheumatology	Multicentre double-blind RCT (n=292) comparing aceclofenac vs. tenoxicam in RA; both groups showed clinical improvement with comparable efficacy and safety
1593574	1992	RCT	The Journal of Rheumatology	RCT (n=102) comparing tenoxicam 20mg OD vs. piroxicam 20mg OD in RA; no difference in efficacy or adverse event rates
2695152	1989	RCT	The British Journal of Clinical Practice	Large double-blind parallel-group trial (n=1,328) in OA and RA comparing tenoxicam and piroxicam; tenoxicam showed slightly greater global assessment improvement
2292331	1990	RCT	The Journal of International Medical Research	Multicentre general-practice study (n=2,963) of oral tenoxicam 20mg/day for 12 weeks in OA/RA; symptom reduction sustained through long-term follow-up
1711963	1991	Review	Drugs	Pharmacology update: tenoxicam efficacy in RA, OA, ankylosing spondylitis and other rheumatic conditions is at least equivalent to other NSAIDs, tolerability comparable to or better than piroxicam
3315620	1987	Review	Drugs	Preliminary review of pharmacodynamics/pharmacokinetics; once-daily 20mg tenoxicam shown effective across RA, OA, ankylosing spondylitis, gout
8137596	1994	Review	Clinical Pharmacokinetics	Clinical pharmacokinetic review: complete oral absorption, ~99% protein binding, supports once-daily dosing in rheumatic disease
3915885	1985	Cohort	European Journal of Rheumatology and Inflammation	Double-blind parallel trials in OA, RA and ankylosing spondylitis; tenoxicam 20mg at least as effective as piroxicam with good tolerance
2512637	1989	Cohort	Scandinavian Journal of Rheumatology Supplement	4-year long-term trial (n=20) of tenoxicam plus basis therapy (gold salts/D-penicillamine) in RA; sustained analgesic/anti-inflammatory benefit
3915889	1985	Cohort	European Journal of Rheumatology and Inflammation	Open multicentric study (n=79) of rectal tenoxicam suppository (20-40mg/day) for 6 weeks in RA and arthrosis

New Zealand Market Information

Tenoxicam currently has no marketing authorizations in New Zealand (market status: not marketed, 0 licenses on record).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are not currently available in the evidence pack — flagged as a blocking data gap for TFDA/Medsafe label review.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Efficacy in RA is well-supported by multiple historical RCTs and reviews (Evidence Level L2), but the only registered clinical trial for this indication is not RA-specific, the drug is unregistered in New Zealand, and core safety/MOA data are missing — so this should advance cautiously rather than as a confirmed go.

To proceed, the following is needed:

TFDA/Medsafe package insert with warnings, contraindications, and drug interaction data (currently a Blocking data gap, DG001)
Confirmed mechanism of action detail (High-priority data gap, DG002)
Documentation of tenoxicam's actual approved indications in markets where it is registered, to properly characterize "original indication"
Assessment of whether pursuing RA is worthwhile given it largely confirms known NSAID class efficacy rather than revealing a novel therapeutic use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.